Meeting
2019 ASCO Annual Meeting
The role of EGFR inhibitors as adjuvant therapy for EGFR mutation positive non-small cell lung cancer.
Authors
Peng Xie
Department of Radiaiton Oncology, Shandong Cancer Hospital and Institute, Jinan, China
Peng Xie , Wenjie Tang , Xiaolin Li , Xindong Sun , Jinming Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8508)
DOI
10.1200/JCO.2019.37.15_suppl.8508
Abstract #
8508
Poster Bd #
264
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Icotinib versus vinorelbine/platinum as adjuvant therapy in stage II-IIIA non-small cell lung cancer with EGFR-mutations: A multicenter, randomized, positive-controlled, phase 3, indication-expanding study (EVIDENCE, CCTC-1501).
First Author: Jianxing He
Poster
2023 ASCO Annual Meeting
EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC).
First Author: Amin Nassar
Poster
2021 ASCO Annual Meeting
Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.
First Author: Chao Lyu
Poster
2019 ASCO Annual Meeting
Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.
First Author: Gregory J. Riely